Search

Your search keyword '"Palazzini M"' showing total 306 results
Start Over Author "Palazzini M"
306 results on '"Palazzini M"'

1. Coexistence of cardiac sarcoidosis and genetic cardiomyopathies: a conundrum

Author

Rossi, V A, primary, Palazzini, M, additional, Gasperetti, A, additional, Brunckhorst, C B, additional, Manka, R, additional, Giannopoulos, A A, additional, Tanner, F C, additional, Medeiros-Domingo, A, additional, Gentile, P, additional, Gruebler, M R, additional, Ammirati, E, additional, Flammer, A J, additional, Ruschitzka, F, additional, Duru, F, additional, and Saguner, A M, additional

Published
2024
Full Text
View/download PDF

10. P408 PREVALENCE CHARACTERISTICS AND OUTCOMES OF COVID 19 ASSOCIATED ACUTE MYOCARDITIS

Author

Palazzini, M, primary, Ammirati, E, additional, Lupi, L, additional, Giannattasio, C, additional, Soriano, F, additional, Pedrotti, P, additional, Briguglia, D, additional, Mapelli, M, additional, Campodonico, J, additional, Agostoni, P, additional, Leonardi, S, additional, Turco, A, additional, Guida, S, additional, Peretto, G, additional, Sala, S, additional, Camici, P, additional, Marzo, F, additional, Grosu, A, additional, Senni, M, additional, Turrini, F, additional, Bramerio, M, additional, Marini, M, additional, Matassini, M, additional, Rizzo, S, additional, Basso, C, additional, De Gaspari, M, additional, Hendren, N, additional, Schmidt, M, additional, Bochaton, T, additional, Piriou, N, additional, Ubarri, A, additional, Van De Heyning, C, additional, Ariza Sole, A, additional, Cannatà, A, additional, Salamanca, J, additional, Lehtonen, J, additional, Huang, F, additional, Adler, E, additional, and Metra, M, additional

Published
2023
Full Text
View/download PDF

11. P227 THE UNEXPECTED CONSEQUENCES OF A 30 METERS FALL

Author

Palazzini, M, primary, Sormani, P, additional, Ammirati, E, additional, Bossi, I, additional, Soriano, F, additional, Colombo, P, additional, Gentile, P, additional, Garascia, A, additional, Oliva, F, additional, and Oreglia, J, additional

Published
2023
Full Text
View/download PDF

13. C84 OUTCOME AND MORPHO–FUNCTIONAL CHANGES ON CARDIAC MAGNETIC RESONANCE IN PATIENT WITH ACUTE MYOCARDITIS FOLLOWING MRNA COVID 19 VACCINATION

Author

Palazzini, M, primary, Ammirati, E, additional, Lupi, L, additional, Garascia, A, additional, Gentile, P, additional, Pedrotti, P, additional, Giannattasio, C, additional, Ciabatti, M, additional, Rossi, V, additional, Ruschitzka, F, additional, Uribarri, A, additional, Vecchio, C, additional, Nassiacos, D, additional, Cereda, A, additional, Tumminiello, G, additional, Piriou, N, additional, Stucchi, M, additional, Peretto, G, additional, Galasso, M, additional, Sala, S, additional, Camici, P, additional, Huang, F, additional, Ianni, U, additional, Procopio, A, additional, Saponara, G, additional, Cimaglia, P, additional, Tomasoni, D, additional, Moroni, F, additional, Turco, A, additional, Di Tano, G, additional, Bollano, E, additional, Moro, C, additional, Abbate, A, additional, Dalla Bona, R, additional, Porto, I, additional, Carugo, S, additional, Campodonico, J, additional, Pontone, G, additional, Grosu, A, additional, Adamo, M, additional, Salamanca, J, additional, Ozieransky, K, additional, Sardo Infirri, L, additional, Cannatà, A, additional, Adler, E, additional, Sinagra, G, additional, Potena, L, additional, Foà, A, additional, Metra, M, additional, and Pieroni, M, additional

Published
2023
Full Text
View/download PDF

16. Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2

Author

Mavromanoli, A.C., Barco, S., Ageno, W., Bouvaist, H., Brodmann, M., Cuccia, C., Couturaud, F., Dellas, C., Dimopoulos, K., Duerschmied, D., Empen, K., Faggiano, P., Ferrari, E., Galie, N., Galvani, M., Ghuysen, A., Giannakoulas, G., Huisman, M.V., Jimenez, D., Kozak, M., Lang, I.M., Meneveau, N., Munzel, T., Palazzini, M., Petris, A.O., Piovaccari, G., Salvi, A., Schellong, S., Schmidt, K.H., Verschuren, F., Schmidtmann, I., Toenges, G., Klok, F.A., Konstantinides, S.V., and PEITHO-2 Investigators

Subjects
Science & Technology, Cardiac & Cardiovascular Systems, Pulmonary embolism, WORKING GROUP, General Medicine, ASSOCIATION, GUIDELINES, EUROPEAN-SOCIETY, DYSFUNCTION, Echocardiography, Dysfunction, Cardiovascular System & Cardiology, MANAGEMENT, HEART, Right ventricle, Intermediate-risk, Cardiology and Cardiovascular Medicine, FOLLOW-UP, Life Sciences & Biomedicine, CARDIOLOGY
Abstract

Background Right ventricular (RV) function plays a critical role in the pathophysiology and acute prognosis of pulmonary embolism (PE). We analyzed the temporal changes of RV function in the cohort of a prospective multicentre study investigating if an early switch to oral anticoagulation in patients with intermediate-risk PE is effective and safe. Methods Echocardiographic and laboratory examinations were performed at baseline (PE diagnosis), 6 days and 6 months. Echocardiographic parameters were classified into categories representing RV size, RV free wall/tricuspid annulus motion, RV pressure overload and right atrial (RA)/central venous pressure. Results RV dysfunction based on any abnormal echocardiographic parameter was present in 84% of patients at baseline. RV dilatation was the most frequently abnormal finding (40.6%), followed by increased RA/central venous pressure (34.6%), RV pressure overload (32.1%), and reduced RV free wall/tricuspid annulus motion (20.9%). As early as day 6, RV size remained normal or improved in 260 patients (64.7%), RV free wall/tricuspid annulus motion in 301 (74.9%), RV pressure overload in 297 (73.9%), and RA/central venous pressure in 254 (63.2%). At day 180, the frequencies slightly increased. The median NT-proBNP level decreased from 1448 pg/ml at baseline to 256.5 on day 6 and 127 on day 180. Conclusion In the majority of patients with acute intermediate-risk PE switched early to a direct oral anticoagulant, echocardiographic parameters of RV function normalised within 6 days and remained normal throughout the first 6 months. Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term. Graphical Abstract

Published
2022

18. SHORT-TERM EFFECT OF SELEXIPAG IN COMPARISON TO PROSTACYCLIN ANALOGUES IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STARTED ON DOUBLE-COMBINATION THERAPY WITH ERA AND PDE-5 INHIBITORS

Author

DARDI, F., primary, MANES, A., additional, BALLERINI, A., additional, GUARINO, D., additional, ROTUNNO, M., additional, DE LORENZIS, A., additional, MAGNANI, I., additional, DONATO, F., additional, BERTOZZI, R., additional, PALAZZINI, M., additional, and GALIÈ, N., additional

Published
2022
Full Text
View/download PDF

19. SURVIVAL OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION LISTED FOR LUNG TRANSPLANTATION

Author

MAGNANI, I., primary, DARDI, F., additional, DOLCI, G., additional, SALVATERRA, E., additional, PALAZZINI, M., additional, PAGANELLI, G.M., additional, GUARINO, D., additional, DE LORENZIS, A., additional, ANTONACCI, F., additional, BALLERINI, A., additional, BERTOZZI, R., additional, ROTUNNO, M., additional, DONATO, F., additional, DADDI, N., additional, SOLLI, P., additional, GALIÈ, N., additional, and MANES, A., additional

Published
2022
Full Text
View/download PDF

22. A CLINICAL AND ECHOCARDIOGRAPHIC SCORE TO DIFFERENTIATE PULMONARY HYPERTENSION DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION FROM IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION: THE PH-HFPEF SCORE

Author

DARDI, F., primary, MANES, A., additional, GUARINO, D., additional, CHIETERA, F., additional, ROTUNNO, M., additional, DE LORENZIS, A., additional, BALLERINI, A., additional, DONATO, F., additional, MAGNANI, I., additional, BERTOZZI, R., additional, PALAZZINI, M., additional, and GALIÈ, N., additional

Published
2022
Full Text
View/download PDF

23. PROGNOSTIC VALUE OF PULMONARY ARTERY DIAMETER IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

Author

DARDI, F., primary, SAIA, F., additional, PALAZZINI, M., additional, DONATO, F., additional, NIRO, F., additional, GUARINO, D., additional, RUSSO, V., additional, TAGLIERI, N., additional, DE LORENZIS, A., additional, ROTUNNO, M., additional, BALLERINI, A., additional, CHIETERA, F., additional, BERTOZZI, R., additional, MANES, A., additional, LOVATO, L., additional, MARROZZINI, C., additional, and GALIÈ, N., additional

Published
2022
Full Text
View/download PDF

28. L’angioplastica delle arterie polmonari nel cuore polmonare cronico tromboembolico: 5 anni di esperienza in Italia

Author

Saia F., Dardi F., Taglieri N., Rotunno M., Manes A., Guarino D., Zuffa E., De Lorenzis A., Magnani I., Ballerini A., Niro F., Martin Suarez S., Pacini D., Gotti E., Galie N., Palazzini M., Saia F., Dardi F., Taglieri N., Rotunno M., Manes A., Guarino D., Zuffa E., De Lorenzis A., Magnani I., Ballerini A., Niro F., Martin Suarez S., Pacini D., Gotti E., Galie N., and Palazzini M.

Subjects
Pulmonary embolism, Chronic thromboembolic pulmonary hypertension, Balloon angioplasty
Abstract

BACKGROUND: Balloon pulmonary angioplasty (BPA) represents a therapeutic option for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) in patients who are not eligible for surgical pulmonary endarterectomy (PEA) or with persistent/recurrent symptomatic pulmonary arterial hypertension after PEA. This study evaluated the safety of BPA during 5 years of experience of the only Italian center systematically performing this procedure. METHODS: The BPA program was activated at the S. Orsola Polyclinic in Bologna in June 2015. Life-threatening periprocedural complications were defined as: death

Published
2021

29. Progressi nel trattamento delle malattie della circolazione polmonare

Author

Galie N., Dardi F., Manes A., Palazzini M., Galie N., Dardi F., Manes A., and Palazzini M.

Subjects
Hypertension, Pulmonary, Chronic Disease, Quality of Life, Endarterectomy, Pulmonary Artery, Pulmonary Embolism, Angioplasty, Balloon, Human
Abstract

Multiple progresses have been achieved in pulmonary vascular diseases in the last decades, including the areas of pulmonary hypertension and pulmonary thromboembolic disease. The increase in knowledge has been accomplished in pathophysiological, clinical and treatment domains and has included as examples the discovery of gene mutations related to the hereditary forms of pulmonary arterial hypertension and the proposals of personalized treatment algorithms in patients with acute pulmonary embolism, chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension, validated in this specific area by more than 45 randomized controlled trials. The diagnostic processes have been refined, increasing the awareness that appropriate and precise diagnosis is essential for the optimal treatment strategy. The drugs approved for pulmonary arterial hypertension are recommended in this group and in specific patients with chronic thromboembolic pulmonary hypertension but are contraindicated in patients with pulmonary hypertension due to left heart and lung diseases. In pulmonary vascular diseases, the therapy cannot be considered as a simple prescription of medications and interventions but is a complex strategy which includes baseline patients' risk stratification, initial therapy, long-term follow-up and treatment adjustments when required. Today, computed tomography pulmonary artery angiography is the gold standard for diagnosis in both acute pulmonary embolism and chronic thromboembolic pulmonary hypertension. In this last condition, the combination with data derived from the right heart catheterization and the traditional pulmonary artery angiography, allows to a team of experts to decide if the patient is a candidate to surgical pulmonary endarterectomy or to percutaneous pulmonary artery balloon angioplasty which may improve symptoms, quality of life and prognosis.

Published
2021

30. Survival of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension listed for lung transplantation

Author

Magnani, I., Dardi, F., Palazzini, M., Zuffa, E., Guarino, D., Daddi, N., giampiero dolci, Antonacci, F., Solli, P., Paganelli, G. M., Lorenzis, A., Rotunno, M., Ballerini, A., Manes, A., and Galie, N.

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Background Lung transplantation (LT) still remains a treatment option for patients with pulmonary arterial hypertension (PAH) and not operable chronic thromboembolic pulmonary hypertension patients (CTEPH). Purpose The study is intended to compare the survival of transplant recipients (TR) and the survival of not-transplanted (NT) patients since listing. Methods We included all patients with PAH and not-operable CTEPH listed for LT. The survival of NT, TR and of all listed patients was evaluated starting from the date of listing (patients were censored as alive at the time of LT). The survival of TR was also evaluated starting from the date of the LT. Results 125 patients were included (112, 90% had PAH). Fifty-eight (46%) patients were transplanted, after a mean waiting time of 1.5±1.3 years. Forty-one patients (33%) died while on the list and 25 (20%) patients were alive on the list on December 2019. The survival of NT patients at 1, 3 and 5 years after listing was 74%, 42%, 33%, respectively. The survival of TR patients at 1, 3 and 5 years after listing was 90%, 70%, 63%, respectively. The survival of all patients since listing (intention to treat analysis) at 1, 3 and 5 years was 85%, 59%, 48% respectively. The survival of TR at 1, 3 and 5 years since transplantation was 63%, 61%, 59%, respectively. Conclusions Despite biases in the comparison of non-randomized groups, the data confirm a better long-term survival since listing of TR as compared with NT PAH or not-operable CTEPH patients. Funding Acknowledgement Type of funding sources: None.

Published
2021

33. Pulmonary arterial hypertension: guidelines and unmet clinical needs

Author

Giuggioli, D., primary, Bruni, C., additional, Cacciapaglia, F., additional, Dardi, F., additional, De Cata, A., additional, Del Papa, N., additional, Iannone, F., additional, Lunardi, C., additional, Maglione, W., additional, Molinaro, F., additional, Palazzini, M., additional, Spinella, A., additional, Tinazzi, E., additional, and Matucci Cerinic, M., additional

Published
2021
Full Text
View/download PDF

36. Prognostic value of pulmonary artery diameter in patients with pulmonary arterial hypertension

Author

Zuffa, E, primary, Dardi, F, additional, Saia, F, additional, Niro, F, additional, Palazzini, M, additional, Russo, V, additional, Taglieri, N, additional, Lovato, L, additional, De Lorenzis, A, additional, Pasca, F, additional, Guarino, D, additional, Magnani, I, additional, Marrozzini, C, additional, Manes, A, additional, and Galie, N, additional

Published
2020
Full Text
View/download PDF

37. Short term effect of Selexipag in comparison to parenteral prostacyclin analogues in pulmonary arterial hypertension patients started on double-combination therapy with ERA and PDE-5 inhibitors

Author

Dardi, F, primary, Zuffa, E, additional, Palazzini, M, additional, Pasca, F, additional, De Lorenzis, A, additional, Guarino, D, additional, Magnani, I, additional, Ballerini, A, additional, Rotunno, M, additional, Manes, A, additional, and Galie, N, additional

Published
2020
Full Text
View/download PDF

38. Cost-effectiveness of cardiovascular risk classification based on Ankle-Brachial Index test in association to Framingham risk score

Author

Grasso, E, primary, Maloberti, A, additional, Cortesi, P.A, additional, Micale, M, additional, Mazzaglia, G, additional, Occhi, L, additional, Palazzini, M, additional, Peretti, A, additional, Cavasin, D, additional, Pansera, F, additional, De Chiara, B, additional, Vallerio, P, additional, Mantovani, L.G, additional, and Giannattasio, C, additional

Published
2020
Full Text
View/download PDF

40. Prognostic Value of Pulmonary Artery Diameter in Patients with Pulmonary Arterial Hypertension

Author

Dardi, F., primary, Saia, F., additional, Niro, F., additional, Palazzini, M., additional, Donato, F., additional, Russo, V., additional, Taglieri, N., additional, Lovato, L., additional, Zuffa, E., additional, De Lorenzis, A., additional, Pasca, F., additional, Guarino, D., additional, Magnani, I., additional, Rotunno, M., additional, Ballerini, A., additional, Marrozzini, C., additional, Manes, A., additional, and Galiè, N., additional

Published
2020
Full Text
View/download PDF

44. Short Term Effect of Selexipag in Comparison to Prostacyclin Analogues in Pulmonary Arterial Hypertension Patients Started on Double-Combination Therapy with ERA and PDE-5 Inhibitors

Author

Dardi, F., primary, Palazzini, M., additional, Zuffa, E., additional, De Lorenzis, A., additional, Guarino, D., additional, Pasca, F., additional, Magnani, I., additional, Rotunno, M., additional, Ballerini, A., additional, Manes, A., additional, and Galiè, N., additional

Published
2020
Full Text
View/download PDF

49. SARS–COV2 INFECTIONS IN HEART TRANSPLANT RECIPIENTS: VACCINES STILL ARE OUR GREATEST WEAPON

Author

Tedeschi, A, Ammirati, E, Garascia, A, Palazzini, M, Masciocco, G, Gentile, P, Monticelli, M, and Leidi, F

Abstract

Long–term clinical follow–ups are needed to assess the effectiveness of vaccine and booster doses against severe acute respiratory syndrome coronavirus 2 (SARS–CoV2) infection for heart transplant (HT) recipients, particularly in an epidemiological landscape characterized by rapidly changing viral variants. Among patients who received HT at Niguarda Hospital from January 2008 to March 2022, we compared the clinical outcomes of those who developed SARS–CoV2 infection between March 2020 and January 2023, according to their vaccination status (vaccinated Vs unvaccinated). Of 377 patients, 98 (25,9%) developed SARS–CoV2 infection during the study period. 24 (27.5 %) developed infection before receiving the vaccination, whilst 74 (75,5%) almost after 2 weeks from receiving the first dose. The unvaccinated cohort demonstrated a higher incidence of death, pneumonia, requiring of oxygen supplementation, non–invasive and invasive ventilation therapy. Furthermore, we assess an additional protective effect against mortality offered from booster doses. Vaccine administration in HT patients is associated with a lower rate of death and severe disease, particularly in those patients who received one or two booster doses.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results